Key facts
- This page summarizes Lorin K. Johnson's Form 4 filing for Edesa Biotech, Inc. (EDSA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 Mar 2022, 18:41.
Lorin K. Johnson - 28 Feb 2022 Form 4 Insider Report for Edesa Biotech, Inc. (EDSA)
- Reporting relationship
- Director
- Issuer ticker
- EDSA
- Reported as of
- 28 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2022, 18:41:06 UTC
- Prior SEC filing
- 23 Jun 2021
- Next SEC filing
- 23 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lorin K. Johnson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lorin K. Johnson filed Form 4 for Edesa Biotech, Inc. (EDSA) on 07 Mar 2022.
Change
- Previous filing in this sequence was filed on 23 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EDSA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +11,000
- Change %
- Price
- $0.000000
- Shares after
- 11,000
- Date
- 28 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 11,000
- Exercise price
- $3.71
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option vests monthly in equal proportions over 12 months beginning on the Grant Date.